Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition

References

• Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, Gultekin M, Luleci G. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proceedings 2006; 38: 1290–1292
   PubMed Web of Science ®Google Scholar
• Alrefai WA, Gill RK. Bile acid transporters: Structure, function, regulation and pathophysiological implications. Pharmaceutical Research 2007; 24: 1803–1823
   PubMed Web of Science ®Google Scholar
• Al-Shawi MK, Polar MK, Omote H, Figler RA. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. Journal of Biology and Chemistry 2003; 278: 52629–52640
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Thervet E, Etienne I, Hurault de Ligny B, Le Meur Y, Touchard G, Buchler M, Laurent-Puig P, Tregouet D, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clinical Pharmacology and Therapy 2004; 75: 422–433
   PubMed Web of Science ®Google Scholar
• Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. Journal of Biology and Chemistry 2004; 279: 22250–22257
   PubMed Web of Science ®Google Scholar
• Bain L, McLachlan J, LeBlanc G. Structure–activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environmental Health Perspectives 1997; 105: 812–818
   PubMed Web of Science ®Google Scholar
• Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Madejczyk MS, Li N. OSTalpha-OSTbeta: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005; 42: 1270–1279
   PubMed Web of Science ®Google Scholar
• Banks WA. Physiology and pathology of the blood–brain barrier: Implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. Journal of Neurovirology 1999; 5: 538–555
   PubMed Web of Science ®Google Scholar
• Bartnicka L, Kurzawski M, Drozdzik A, Plonska-Gosciniak E, Gornik W, Drozdzik M. Effect of ABCB1 (MDR1) 3435C > T and 2677G > A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients. Pharmacology Reports 2007; 59: 323–329
   PubMed Web of Science ®Google Scholar
• Bartra J, Valero AL, Del Cuvillo A, Davila I, Jauregui I, Montoro J, Mullol J, Sastre J. Interactions of the H1 antihistamines. Journal of Investigations in Allergology and Clinical Immunology 2006; 16(Suppl. 1)29–36
   PubMedGoogle Scholar
• Begley DJ. ABC transporters and the blood–brain barrier. Current Pharmaceutical Design 2004; 10: 1295–1312
   PubMed Web of Science ®Google Scholar
• Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proceedings of the National Academy of Sciences, USA 1998; 95: 12208–12213
   PubMed Web of Science ®Google Scholar
• Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic, and cytogenetic studies. Cancer Research 1970; 30: 1174–1184
   PubMed Web of Science ®Google Scholar
• Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annual Reviews in Biochemistry 2002; 71: 537–592
   PubMed Web of Science ®Google Scholar
• Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. Journal of Psychiatry Research, 2006; 42: 89–97
   PubMed Web of Science ®Google Scholar
• Buxbaum E. Co-operating ATP sites in the multiple drug resistance transporter Mdr1. European Journal of Biochemistry 1999; 265: 54–63
   PubMedGoogle Scholar
• Cabrera MA, Gonzalez I, Fernandez C, Navarro C, Bermejo M. A topological substructural approach for the prediction of P-glycoprotein substrates. Journal of Pharmaceutical Sciences 2006; 95: 589–606
   PubMed Web of Science ®Google Scholar
• Canaparo R, Finstrom N, Serpe L, Nordmark A. Expression of CYP3A Isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clinical and Experimental Pharmacology and Physiology 2007; 34: 1138–1144
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clinical Pharmacology and Therapy 2001; 69: 169–174
   PubMed Web of Science ®Google Scholar
• Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clinical Chemistry and Laboratory Medicine 2003; 41: 1345–1350
   PubMed Web of Science ®Google Scholar
• Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences 2004; 21: 25–51
   PubMed Web of Science ®Google Scholar
• Chandra P, Brouwer KL. The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharmaceutical Research 2004; 21: 719–735
   PubMed Web of Science ®Google Scholar
• Chaudhary P, Roninson I. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. Journal of the National Cancer Institute 1993; 85: 632–639
   PubMed Web of Science ®Google Scholar
• Chin K, Tanaka S, Darlington G. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. Journal of Biology and Chemistry 1990; 265: 221–226
   PubMed Web of Science ®Google Scholar
• Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: Progress, pitfalls, and promise. Clinical Pharmacology and Therapy 2007; 81: 265–269
   PubMed Web of Science ®Google Scholar
• Cianchetta G, Singleton RW, Zhang M, Wildgoose M, Giesing D, Fravolini A, Cruciani G, Vaz RJ. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. Journal of Medicine and Chemistry 2005; 48: 2927–2935
   PubMed Web of Science ®Google Scholar
• Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: A special look at the heart. Pharmacology Reviews 2006; 58: 244–258
   PubMed Web of Science ®Google Scholar
• Crivori P, Reinach B, Pezzetta D, Poggesi I. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Molecular Pharmacology 2006; 3: 33–44
   PubMed Web of Science ®Google Scholar
• Crouthamel MH, Wu D, Yang Z, Ho RJ. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. Journal of Pharmaceutical Sciences 2006; 95: 2767–2777
   PubMed Web of Science ®Google Scholar
• Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. Journal of Pharmacology and Experimental Therapy 2002; 300: 1036–1045
   PubMed Web of Science ®Google Scholar
• Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmacology Reviews 2006; 58: 140–161
   PubMed Web of Science ®Google Scholar
• De Boer AG, Gaillard PJ. Drug targeting to the brain. Annual Reviews in Pharmacology and Toxicology 2007; 47: 323–355
   PubMed Web of Science ®Google Scholar
• De Boer AG, Van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood–brain barrier. Annual Reviews in Pharmacology and Toxicology 2003; 43: 629–656
   PubMed Web of Science ®Google Scholar
• Dean M. The human ATP-binding cassette (ABC) transporter superfamily. National Center for Biotechnology Information (NCBI), National library of Medicine, Bethesda, MDUSA 2002
   Google Scholar
• Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiology Reviews 2006; 86: 849–899
   PubMed Web of Science ®Google Scholar
• Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, Sugiyama Y. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney International 2004; 65: 162–174
   PubMed Web of Science ®Google Scholar
• Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. British Journal of Clinical Pharmacology 2002; 53: 526–534
   PubMed Web of Science ®Google Scholar
• Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: A possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003; 13: 259–263
   PubMedGoogle Scholar
• Druley TE, Stein WD, Roninson IB. Analysis of MDR1 P-glycoprotein conformational changes in permeabilized cells using differential immunoreactivity. Biochemistry 2001a; 40: 4312–4322
   PubMed Web of Science ®Google Scholar
• Druley TE, Stein WD, Ruth A, Roninson IB. P-glycoprotein-mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation. Biochemistry 2001b; 40: 4323–4331
   PubMed Web of Science ®Google Scholar
• Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. Application of three-dimensional quantitative structure–activity relationships of P-glycoprotein inhibitors and substrates. Molecular Pharmacology 2002; 61: 974–981
   PubMed Web of Science ®Google Scholar
• Evers R, Kool M, Van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. Journal of Clinical Investigation 1998; 101: 1310–1319
   PubMed Web of Science ®Google Scholar
• Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 2002; 359: 30–36
   PubMed Web of Science ®Google Scholar
• Foote CJ, Greer W, Kiberd B, Fraser A, Lawen J, Nashan B, Belitsky P. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 2007; 83: 1380–1384
   PubMed Web of Science ®Google Scholar
• Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, et al. Expression polymorphism of the blood–brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12: 529–534
   PubMedGoogle Scholar
• Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. Journal of Biology and Chemistry 1995; 270: 25672–25677
   PubMed Web of Science ®Google Scholar
• Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. Journal of Biology and Chemistry 2001; 276: 14581–14587
   PubMed Web of Science ®Google Scholar
• Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochimica et Biophysica Acta 2007; 1773: 283–308
   PubMed Web of Science ®Google Scholar
• Girardin F. Membrane transporter proteins: A challenge for CNS drug development. Dialogues in Clinical Neurosciences 2006; 8: 311–321
   PubMedGoogle Scholar
• Goreva OB, Grishanova AY, Domnikova NP, Mukhin OV, Lyakhovich VV. MDR1 Gene C1236T and C6 + 139T polymorphisms in the Russian population: Associations with predisposition to lymphoproliferative diseases and drug resistance. Bulletin in Experimental Biology and Medicine 2004; 138: 404–406
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews in Cancer 2002; 2: 48–58
   PubMed Web of Science ®Google Scholar
• Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. Journal of Pharmaceutical Sciences. 2007, doi: 10.1002/jps.21169
   Web of Science ®Google Scholar
• Hafkemeyer P, Dey S, Ambudkar SV, Hrycyna CA, Pastan I, Gottesman MM. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. Biochemistry 1998; 37: 16400–16409
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Davis TP. The blood–brain barrier/neurovascular unit in health and disease. Pharmacology Reviews 2005; 57: 173–185
   PubMed Web of Science ®Google Scholar
• Hennessy M, Kelleher D, Spiers J, Barry M. St Johns wort increases expression of P-glycoprotein: Implications for drug interactions. British Journal of Clinical Pharmacology 2002; 53: 75–82
   PubMed Web of Science ®Google Scholar
• Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007; 446: 749–757
   PubMed Web of Science ®Google Scholar
• Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. Structure of the multidrug resistance P-glycoprotein. Seminars in Cancer Biology 1997; 8: 135–142
   PubMed Web of Science ®Google Scholar
• Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: Discrimination of critical variants using a gene-wide haplotype tagging approach. Human Molecular Genetics 2006; 15: 797–805
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences, USA 2000; 97: 3473–3478
   PubMed Web of Science ®Google Scholar
• Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, Unadkat JD. Verapamil P-glycoprotein transport across the rat blood–brain barrier: Cyclosporine, a concentration inhibition analysis, and comparison with human data. Journal of Pharmacology and Experimental Therapy 2006; 317: 704–710
   PubMed Web of Science ®Google Scholar
• Huang J, Ma G, Muhammad I, Cheng Y. Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm. Journal of Chemical Information Modeling 2007a; 47: 1638–1647
   PubMed Web of Science ®Google Scholar
• Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: Study design, data analysis, and implications for dosing and labeling. Clinical Pharmacology and Therapy 2007b; 81: 298–304
   PubMed Web of Science ®Google Scholar
• Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney International 2000; 58: 944–958
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opinions in Drug Metabolism and Toxicology 2006; 2: 351–366
   PubMed Web of Science ®Google Scholar
• Jin S, Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Molecular Cell Biology 1998; 18: 4377–4384
   PubMed Web of Science ®Google Scholar
• Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Molecular Cell Biology 2003; 23: 7902–7908
   PubMed Web of Science ®Google Scholar
• Julien M, Kajiji S, Kaback RH, Gros P. Simple purification of highly active biotinylated P-glycoprotein: Enantiomer-specific modulation of drug-stimulated ATPase activity. Biochemistry 2000; 39: 75–85
   PubMed Web of Science ®Google Scholar
• Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, et al. Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: In comparison with rOAT1. Life Sciences 2002; 70: 1861–1874
   PubMed Web of Science ®Google Scholar
• Katoh T, Saitoh H, Ohno N, Tateno M, Nakamura T, Dendo I, Kobayashi S, Nagasawa K. Drug interaction between mosapride and erythromycin without electrocardiographic changes. Japan Heart Journal 2003; 44: 225–234
   PubMedGoogle Scholar
• Kauffmann HM, Pfannschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JI, Schrenk D. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 2002; 171: 137–146
   PubMed Web of Science ®Google Scholar
• Kaya P, Gunduz U, Arpaci F, Ural AU, Guran S. Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients. American Journal of Hematology 2005; 80: 26–34
   PubMed Web of Science ®Google Scholar
• Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clinical Pharmacokinetics 2004; 43: 595–612
   PubMed Web of Science ®Google Scholar
• Kearney BP, Sayre JR, Flaherty JF, Chen SS, Kaul S, Cheng AK. Drug–drug and drug–food interactions between tenofovir disoproxil fumarate and didanosine. Journal of Clinical Pharmacology 2005; 45: 1360–1367
   PubMed Web of Science ®Google Scholar
• Kedmi M, Maayan S, Cohen SB, Hauzi M, Rund D. MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease. AIDS Patient Care STDs 2007; 21: 653–658
   PubMed Web of Science ®Google Scholar
• Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clinical Pharmacology and Therapy 2001; 70: 189–199
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kakehi Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. Journal of Urology 1996; 156: 506–511
   PubMed Web of Science ®Google Scholar
• Kimura Y, Morita S-Y, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Science 2007; 98: 1303–1310
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors. Current Drug Metabolism 2005; 6: 309–328
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998; 92: 73–82
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. Journal of Lipid Research 2002; 43: 359–364
   PubMed Web of Science ®Google Scholar
• Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451–2458
   PubMed Web of Science ®Google Scholar
• Kotb R, Vincent I, Dulioust A, Peretti D, Taburet AM, Delfraissy JF, Goujard C. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. European Journal of Haematology 2006; 76: 269–271
   PubMed Web of Science ®Google Scholar
• Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481–494
   PubMedGoogle Scholar
• Kusch-Poddar M, Drewe J, Fux I, Gutmann H. Evaluation of the immortalized human brain capillary endothelial cell line BB19 as a human cell culture model for the blood–brain barrier. Brain Research 2005; 1064: 21–31
   PubMed Web of Science ®Google Scholar
• Kuwano M, Oda Y, Izumi H, Yang S-J. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Molecular Cancer Therapy 2004; 3: 1485–1492
   PubMed Web of Science ®Google Scholar
• Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, Kohno K. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Science 2003; 94: 9–14
   PubMed Web of Science ®Google Scholar
• Kwan P, Baum L, Wong V, Ng PW, Lui CH, Sin NC, Hui AC, Yu E, Wong LK. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy and Behavior 2007; 11: 112–117
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie M. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005; 46: 224–235
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Izzedine H, Karie S, Hulot JS, Baumelou A, Deray G. Renal tubular drug transporters. Nephron Physiology 2006; 103: 97–106
   PubMed Web of Science ®Google Scholar
• Ledoux S, Yang R, Friedlander G, Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: Role of endoplasmic reticulum stress response. Cancer Research 2003; 63: 7284–7290
   PubMed Web of Science ®Google Scholar
• Lee CG, Tang K, Cheung YB, Wong LP, Tan C, Shen H, Zhao Y, Pavanni R, Lee EJ, Wong MC, et al. MDR1, the blood–brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. Journal of Medicine and Genetics 2004; 41: e60
   PubMed Web of Science ®Google Scholar
• Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: A critical review and recommendations for future research. Pharmacogenomics Journal 2007; 7: 154–179
   PubMed Web of Science ®Google Scholar
• Lin JH. Transporter-mediated drug interactions: Clinical implications and in vitro assessment. Expert Opinions in Drug Metabolism and Toxicology 2007; 3: 81–92
   PubMed Web of Science ®Google Scholar
• Linton KJ. Structure and function of ABC transporters. Physiology (Bethesda) 2007; 22: 122–130
   PubMed Web of Science ®Google Scholar
• Linton KJ, Higgins CF. Structure and function of ABC transporters: The ATP switch provides flexible control. Pflugers Archives 2007; 453: 555–567
   PubMed Web of Science ®Google Scholar
• Locher KP. Structure and mechanism of ABC transporters. Current Opinions on Structural Biology 2004; 14: 426–431
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates. Biochemistry 1999a; 38: 5124–5129
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane. Journal of Biology and Chemistry 1999b; 274: 35388–35392
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. Journal of Biology and Chemistry 2000; 275: 39272–39278
   PubMed Web of Science ®Google Scholar
• Loo TW, Bartlett MC, Clarke DM. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. Journal of Biology and Chemistry 2003a; 278: 39706–39710
   PubMed Web of Science ®Google Scholar
• Loo TW, Bartlett MC, Clarke DM. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. Journal of Biology and Chemistry 2003b; 278: 13603–13606
   PubMed Web of Science ®Google Scholar
• Loo TW, Bartlett MC, Clarke DM. Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein. Journal of Biology and Chemistry 2004; 279: 18232–18238
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Blood–brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86–98
   PubMedGoogle Scholar
• Ma JF, Grant G, Melera PW. Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal. Molecular Pharmacology 1997; 51: 922–930
   PubMed Web of Science ®Google Scholar
• Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. European Journal of Clinical Pharmacology 2006; 62: 225–233
   PubMed Web of Science ®Google Scholar
• Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metabolism and Disposition 2005; 33: 956–962
   PubMed Web of Science ®Google Scholar
• Makinson A, Martelli N, Peyriere H, Turriere C, Le Moing V, Reynes J. Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. European Journal of Haematology 2007; 78: 358–360
   PubMed Web of Science ®Google Scholar
• Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12: 927–941
   PubMed Web of Science ®Google Scholar
• Marin JJ, Macias RI, Briz O, Perez MJ, Serrano MA. Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver–placenta–maternal liver pathway. Annals of Hepatology 2005; 4: 70–76
   PubMedGoogle Scholar
• Martin C, Berridge G, Higgins CF, Callaghan R. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. British Journal of Pharmacology 1997; 122: 765–771
   PubMed Web of Science ®Google Scholar
• Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Molecular Pharmacology 2000a; 58: 624–632
   PubMed Web of Science ®Google Scholar
• Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 2000b; 39: 11901–11906
   PubMed Web of Science ®Google Scholar
• Martin C, Higgins CF, Callaghan R. The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein. Biochemistry 2001; 40: 15733–15742
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clinical Pharmacology and Therapy 2004; 75: 13–33
   PubMed Web of Science ®Google Scholar
• Matsuzaki Y, Nakano A, Jiang QJ, Pulkkinen L, Uitto J. Tissue-specific expression of the ABCC6 gene. Journal of Investigative Dermatology 2005; 125: 900–905
   PubMed Web of Science ®Google Scholar
• Mealey K. Therapeutic implications of the MDR-1 gene. Journal of Veterinary Pharmacology and Therapeutics 2004; 27: 257–264
   PubMed Web of Science ®Google Scholar
• Mechetner EB, Schott B, Morse BS, Stein WD, Druley T, Davis KA, Tsuruo T, Roninson IB. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proceedings of the National Academy of Sciences, USA 1997; 94: 12908–12913
   PubMed Web of Science ®Google Scholar
• Mercier C, Masseguin C, Roux F, Gabrion J, Scherrmann JM. Expression of P-glycoprotein (ABCB1) and Mrp1 (ABCC1) in adult rat brain: Focus on astrocytes. Brain Research 2004; 1021: 32–40
   PubMed Web of Science ®Google Scholar
• Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T. Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749–1756
   PubMed Web of Science ®Google Scholar
• Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, Manautou JE. Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. Journal of Pharmacology and Experimental Therapy 2006; 317: 537–545
   PubMed Web of Science ®Google Scholar
• Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochemistry and Pharmacology 2003; 65: 1843–1852
   PubMed Web of Science ®Google Scholar
• Morris DI, Greenberger LM, Bruggemann EP, Cardarelli C, Gottesman MM, Pastan I, Seamon KB. Localization of the forskolin labeling sites to both halves of P-glycoprotein: Similarity of the sites labeled by forskolin and prazosin. Molecular Pharmacology 1994; 46: 329–337
   PubMed Web of Science ®Google Scholar
• Nagy L, Schule R, Gronemeyer H. Twenty years of nuclear receptors: Conference on Nuclear Receptors: From Chromatin to Disease. EMBO Report 2006; 7: 579–584
   PubMed Web of Science ®Google Scholar
• Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clinical Pharmacology and Therapy 2003; 73: 554–565
   PubMed Web of Science ®Google Scholar
• Ohga T, Koike K, Ono M, Makino Y. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin c, and ultraviolet light. Cancer Research 1996; 56: 4224–4228
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006; 44: 778–787
   PubMed Web of Science ®Google Scholar
• Pechandova K, Buzkova H, Slanar O, Perlik F. Polymorphisms of the MDR1 gene in the Czech population. Folia Biology (Praha) 2006; 52: 184–189
   PubMed Web of Science ®Google Scholar
• Penzotti JE, Lamb ML, Evensen E, Grootenhuis PD. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. Journal of Medicine and Chemistry 2002; 45: 1737–1740
   PubMed Web of Science ®Google Scholar
• Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, et al. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Research 2001; 61: 6034–6037
   PubMed Web of Science ®Google Scholar
• Piddock LJ. Multidrug-resistance efflux pumps — not just for resistance. Nature Reviews in Microbiology 2006; 4: 629–636
   PubMed Web of Science ®Google Scholar
• Pleban K, Kopp S, Csaszar E, Peer M, Hrebicek T, Rizzi A, Ecker GF, Chiba P. P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: A combined photoaffinity labeling-protein homology modeling approach. Molecular Pharmacology 2005; 67: 365–374
   PubMed Web of Science ®Google Scholar
• Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, Pastan I. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 1998; 37: 5010–5019
   PubMed Web of Science ®Google Scholar
• Raub TJ. P-glycoprotein recognition of substrates and circumvention through rational drug design. Molecular Pharmacology 2006; 3: 3–25
   PubMed Web of Science ®Google Scholar
• Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR. Mechanism of active renal tubular efflux of tenofovir. Antimicrobial Agents and Chemotherapy 2006; 50: 3297–3304
   PubMed Web of Science ®Google Scholar
• Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrobial Agents and Chemotherapy 2004; 48: 1089–1095
   PubMed Web of Science ®Google Scholar
• Romsicki Y, Sharom F. The ATPase and ATP-binding functions of P-glycoprotein modulation by interaction with defined phospholipids. European Journal of Biochemistry 1998; 256: 170–178
   PubMedGoogle Scholar
• Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. Journal of Biology and Chemistry 2003; 278: 8294–8299
   PubMed Web of Science ®Google Scholar
• Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, et al. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO Journal 2001; 20: 5615–5625
   PubMed Web of Science ®Google Scholar
• Rund D, Azar I, Shperling O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Advances in Experimental Medicine and Biology 1999; 457: 71–75
   PubMed Web of Science ®Google Scholar
• Ruth A, Stein WD, Rose E, Roninson IB. Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein. Biochemistry 2001; 40: 4332–4339
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharmaceutical Research 2001; 18: 1400–1404
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Ambudkar SV. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proceedings of the National Academy of Sciences, USA 2000; 97: 2515–2520
   PubMed Web of Science ®Google Scholar
• Schaefer M, Roots I, Gerloff T. In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenetics and Genomics 2006; 16: 855–861
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358: 383–384
   PubMed Web of Science ®Google Scholar
• Seelig A. A general pattern for substrate recognition by P-glycoprotein. European Journal of Biochemistry 1998; 251: 252–261
   PubMedGoogle Scholar
• Seelig A, Landwojtowicz E. Structure–activity relationship of P-glycoprotein substrates and modifiers. European Journal of Pharmaceutical Sciences 2000; 12: 31–40
   PubMed Web of Science ®Google Scholar
• Sekine T, Miyazaki H, Endou H. Molecular physiology of renal organic anion transporters. American Journal of Physiology Renal Physiology 2006; 290: F251–261
   PubMed Web of Science ®Google Scholar
• Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. European Journal of Biochemistry 1997; 250: 130–137
   PubMedGoogle Scholar
• Shibahara K, Uchiumi T, Fukuda T, Kura S, Tominaga Y, Maehara Y, Kohno K, Nakabeppu Y, Tsuzuki T, Kuwano M. Targeted disruption of one allele of the Y-box binding protein-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C. Cancer Sciences 2004; 95: 348–353
   PubMed Web of Science ®Google Scholar
• Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S, Van Veen HW. New light on multidrug binding by an ATP-binding-cassette transporter. Trends in Pharmacology Sciences 2006; 27: 195–203
   PubMed Web of Science ®Google Scholar
• Shiraga K, Sakaguchi K, Senoh T, Ohta T. Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicin-resistant sublines. Journal of Gastroenterology and Hepatology 2001; 16: 460–466
   PubMed Web of Science ®Google Scholar
• Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New England Journal of Medicine 2003; 348: 1442–1448
   PubMed Web of Science ®Google Scholar
• Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain: Focus on brain lymphoma. Clinical Pharmacokinetics 2002; 41: 171–186
   PubMed Web of Science ®Google Scholar
• Sills GJ, Kwan P, Butler E, de Lange EC, Van den Berg DJ, Brodie MJ. P-glycoprotein-mediated efflux of antiepileptic drugs: Preliminary studies in mdr1a knockout mice. Epilepsy and Behavior 2002; 3: 427–432
   PubMed Web of Science ®Google Scholar
• Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005; 46: 643–647
   PubMed Web of Science ®Google Scholar
• Skalli S, Zaid A, Soulaymani R. Drug interactions with herbal medicines. Therapy and Drug Monitoring 2007; 29: 679–686
   PubMed Web of Science ®Google Scholar
• Song J, Melera PW. Transmembrane domain (TM) 9 represents a novel site in P-glycoprotein that affects drug resistance and cooperates with TM6 to mediate [125I]iodoarylazidoprazosin labeling. Molecular Pharmacology 2001; 60: 254–261
   PubMed Web of Science ®Google Scholar
• Sonveaux N, Shapiro AB, Goormaghtigh E, Ling V, Ruysschaert JM. Secondary and tertiary structure changes of reconstituted P-glycoprotein. A Fourier transform attenuated total reflection infrared spectroscopy analysis. Journal of Biology and Chemistry 1996; 271: 24617–24624
   PubMed Web of Science ®Google Scholar
• Sonveaux N, Vigano C, Shapiro AB, Ling V, Ruysschaert JM. Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein. A tryptophan fluorescence quenching analysis. Journal of Biology and Chemistry 1999; 274: 17649–17654
   PubMed Web of Science ®Google Scholar
• Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proceedings of the National Academy of Sciences, USA 2001; 98: 3369–3374
   PubMed Web of Science ®Google Scholar
• Staudinger JL, Madan A, Carol KM, Parkinson A. Regulation of drug transporter gene expression by nuclear receptors. Drug Metabolism and Disposition 2003; 31: 523–527
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nature Reviews in Drug Discovery 2006; 5: 219–234
   PubMed Web of Science ®Google Scholar
• Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proceedings 2005; 37: 1730–1732
   PubMed Web of Science ®Google Scholar
• Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, Mulley JC, Berkovic SF. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004; 63: 1090–1092
   PubMed Web of Science ®Google Scholar
• Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clinical Pharmacokinetics 2002; 41: 81–92
   PubMed Web of Science ®Google Scholar
• Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metabolism and Disposition 2003; 31: 1296–1299
   PubMed Web of Science ®Google Scholar
• Terada T, Inui K. Peptide transporters: Structure, function, regulation and application for drug delivery. Current Drug Metabolism 2004; 5: 85–94
   PubMed Web of Science ®Google Scholar
• Terasaki T, Ohtsuki S. Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood–brain barrier: An overview of biology and methodology. NeuroRx 2005; 2: 63–72
   PubMedGoogle Scholar
• Thiebaut F, Tsuruo T, Hamada H, Gottesman M. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences, USA 1987; 84: 7735–7738
   PubMed Web of Science ®Google Scholar
• Tian Q, Zhang J, Chan E, Duan W, Zhou SF. Multidrug resistance proteins (MRPs) and implication in drug development. Drug Development and Research 2005; 51: 1–18
   Web of Science ®Google Scholar
• Tombline G, Bartholomew LA, Urbatsch IL, Senior AE. Combined mutation of catalytic glutamate residues in the two nucleotide binding domains of P-glycoprotein generates a conformation that binds ATP and ADP tightly. Journal of Biology and Chemistry 2004; 279: 31212–31220
   PubMed Web of Science ®Google Scholar
• Trauner M, Boyer JL. Bile salt transporters: Molecular characterization, function, and regulation. Physiology Reviews 2003; 83: 633–671
   PubMed Web of Science ®Google Scholar
• Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. Journal of Clinical Pharmacology 2007; 47: 566–578
   PubMed Web of Science ®Google Scholar
• Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies. Seminars in Oncology 2004; 31: 16–35
   PubMed Web of Science ®Google Scholar
• Van de Water FM, Masereeuw R, Russel FG. Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug Metabolism Reviews 2005; 37: 443–471
   PubMed Web of Science ®Google Scholar
• Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. European Journal of Clinical Pharmacology 2003; 58: 809–812
   PubMed Web of Science ®Google Scholar
• Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO Journal 1982; 1: 945–951
   PubMed Web of Science ®Google Scholar
• Wang RB, Kuo CL, Lien LL, Lien EJ. Structure–activity relationship: Analyses of p-glycoprotein substrates and inhibitors. Journal of Clinical Pharmaceutical Therapy 2003; 28: 203–228
   PubMed Web of Science ®Google Scholar
• Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. Journal of Pharmacology and Experimental Therapy 2004; 310: 1199–1207
   PubMed Web of Science ®Google Scholar
• Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. Aids 2005; 19: 1617–1625
   PubMed Web of Science ®Google Scholar
• Yamada T, Kato Y, Kusuhara H, Lemaire M, Sugiyama Y. Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: Possible involvement of P-glycoprotein. Biology and Pharmaceutics Bulletin 1998; 21: 874–878
   PubMed Web of Science ®Google Scholar
• Yang JJ, Ann DK, Kannan R, Lee VH. Multidrug resistance protein 1 (MRP1) in rabbit conjunctival epithelial cells: Its effect on drug efflux and its regulation by adenoviral infection. Pharmaceutical Research 2007; 24: 1490–1500
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochemistry and Pharmacology 2005; 70: 1823–1831
   PubMed Web of Science ®Google Scholar
• Yu XQ, Xue CC, Wang G, Zhou SF. Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Current Drug Metabolism 2007; 8: 787–802
   PubMed Web of Science ®Google Scholar
• Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, Bowman P, Burckart GJ. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Human Immunology 2002; 63: 765–770
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. Journal of Psychopharmacology 2004; 18: 262–276
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Therapy and Drug Monitoring 2007a; 29: 687–710
   PubMed Web of Science ®Google Scholar
• Zhou SF, Zhou ZW, Li CG, Chen X, Yu X, Xue CC, Herington A. Identification of drugs that interact with herbs in drug development. Drug Discovery Today 2007b; 12: 664–673
   PubMed Web of Science ®Google Scholar